Nocion completes patient enrolment in Phase IIb ASPIRE trial

Nocion Therapeutics has completed patient enrolment in its Phase IIb ASPIRE study assessing taplucainium as a treatment for rCC/uCC. The primary endpoint of the trial is the change in 24-hour cough frequency from baseline to the end of treatment, as assessed by VitaloJAK Cough Counts. Chronic cough lasts longer than eight weeks, causing significant physical, social, and psychosocial impact. Credit: NMK-Studio / Shutterstock.com. Nocion Therapeutics has completed patient enrolment in its Phase IIb ASPIRE study assessing taplucainium as a treatment for refractory or unexplained chronic cough (rCC/uCC). The double-blind, placebo-controlled, randomised trial has enrolled 240 adult patients at over 100…

Source: Clinical Trials Arena